Gene Targeting of Cytokines and the Mitogen-Activated Protein Kinase Pathways in Human Rheumatoid Synovium Using the Severe Combined Immunodeficiency Mouse Model

[1]  W. B. Berg.  Joint inflammation and cartilage destruction may occur uncoupled , 2004, Springer Seminars in Immunopathology.

[2]  W. Mohr,et al.  Proliferation of pannus tissue cells in rheumatoid arthritis , 2004, Rheumatology International.

[3]  C. Gabay,et al.  Treatment of rheumatoid arthritis with IL-1 inhibitors , 2004, Springer Seminars in Immunopathology.

[4]  U. Müller-Ladner,et al.  Delivery of antisense constructs and ribozymes to inhibit cartilage destruction in the SCID mouse model of RA , 2001, Arthritis Research.

[5]  G. Firestein,et al.  Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion. , 2001, Arthritis and rheumatism.

[6]  P. Robbins,et al.  Gene therapy for rheumatoid arthritis. , 2001, Expert opinion on biological therapy.

[7]  G. Firestein,et al.  Modulation of fibroblast-mediated cartilage degradation by articular chondrocytes in rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[8]  H. Ronday,et al.  Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of a cell surface-targeted plasmin inhibitor. , 2000, Arthritis and rheumatism.

[9]  R. Gay,et al.  Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[10]  R. Gay,et al.  Gene transfer: from concept to therapy , 2000, Current opinion in rheumatology.

[11]  U. Müller-Ladner,et al.  Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[12]  Thomas Pap,et al.  Activation of synovial fibroblasts in rheumatoid arthritis: lack of expression of the tumour suppressor PTEN at sites of invasive growth and destruction , 1999, Arthritis research.

[13]  H. Ronday,et al.  Cartilage invasion by rheumatoid synovial fibroblasts in vivo is inhibited by gene transfer of a cell surface-targeted plasmin inhibitor: abstract , 2000 .

[14]  S. Santavirta,et al.  Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis , 1999, Annals of the rheumatic diseases.

[15]  A. Manning,et al.  Jun N-terminal kinase in rheumatoid arthritis. , 1999, The Journal of pharmacology and experimental therapeutics.

[16]  P. Petrow,et al.  Characterization of collagenase 3 (matrix metalloproteinase 13) messenger RNA expression in the synovial membrane and synovial fibroblasts of patients with rheumatoid arthritis. , 1999, Arthritis and rheumatism.

[17]  C. Weyand,et al.  T-cell responses in rheumatoid arthritis: systemic abnormalities-local disease. , 1999, Current opinion in rheumatology.

[18]  F. Canovas,et al.  Systemic viral interleukin-10 gene delivery prevents cartilage invasion by human rheumatoid synovial tissue engrafted in SCID mice. , 1999, Arthritis and rheumatism.

[19]  G L Johnson,et al.  Organization and regulation of mitogen-activated protein kinase signaling pathways. , 1999, Current opinion in cell biology.

[20]  P. Robbins,et al.  Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model. , 1999, Arthritis and rheumatism.

[21]  R. Lafyatis,et al.  Integrin engagement regulates proliferation and collagenase expression of rheumatoid synovial fibroblasts. , 1999, Journal of immunology.

[22]  B. Bresnihan,et al.  Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. , 1999, Rheumatology.

[23]  J. Dean,et al.  Protein kinase cascades in intracellular signalling by interleukin-I and tumour necrosis factor. , 1999, Biochemical Society symposium.

[24]  R. Rau,et al.  Clinical trials on biologics in rheumatoid arthritis. , 1998, International journal of clinical pharmacology and therapeutics.

[25]  P. Petrow,et al.  Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. , 1998, The Journal of rheumatology.

[26]  S. Gay,et al.  Gene therapy in osteoarticular diseases: where are we? , 1998, Immunology today.

[27]  E. Keystone,et al.  IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. , 1998, Rheumatic diseases clinics of North America.

[28]  F. Breedveld,et al.  Poor expression of T cell-derived cytokines and activation and proliferation markers in early rheumatoid synovial tissue. , 1998, Clinical immunology and immunopathology.

[29]  U. Müller-Ladner,et al.  Molecular biology of cartilage and bone destruction. , 1998, Current opinion in rheumatology.

[30]  T. Ochi,et al.  Possible correction of abnormal rheumatoid arthritis synovial cell function by jun D transfection in vitro. , 1998, Arthritis and rheumatism.

[31]  S. Santavirta,et al.  Synovial lining, endothelial and inflammatory mononuclear cell proliferation in synovial membranes in psoriatic and reactive arthritis: a comparative quantitative morphometric study. , 1998, British journal of rheumatology.

[32]  A. Manning,et al.  AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. , 1998, Autoimmunity.

[33]  J. Banchereau,et al.  An update on interleukin-4 and its receptor. , 1997, European cytokine network.

[34]  Y. Kaneda,et al.  Ribozyme-based gene cleavage approach to chronic arthritis associated with human T cell leukemia virus type I: induction of apoptosis in synoviocytes by ablation of HTLV-I tax protein. , 1997, Arthritis and rheumatism.

[35]  G. H. Rank,et al.  Colocalization of antisense RNAs and ribozymes with their target mRNAs. , 1997, Genome.

[36]  M. Lukoschek,et al.  Differential expression and functional behaviour of the αv and β3 integrin subunits in cytokine stimulated fibroblast-like cells derived from synovial tissue of rheumatoid arthritis and osteoarthritis in vitro , 1997, Annals of the rheumatic diseases.

[37]  C. Weyand,et al.  The molecular basis of rheumatoid arthritis , 1997, Journal of Molecular Medicine.

[38]  D. Green,et al.  Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Santavirta,et al.  Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. , 1997, Arthritis and rheumatism.

[40]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[41]  U. Müller-Ladner,et al.  Cellular pathways of joint destruction. , 1997, Current opinion in rheumatology.

[42]  P. Robbins,et al.  Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective. , 1997, Journal of immunology.

[43]  L. Moreland,et al.  Biologic agents for treating rheumatoid arthritis. Concepts and progress. , 1997, Arthritis and rheumatism.

[44]  P. Emery,et al.  Inhibition of T cell apoptosis in the rheumatoid synovium. , 1997, The Journal of clinical investigation.

[45]  M. Lukoschek,et al.  Increased expression of integrins on fibroblast-like synoviocytes from rheumatoid arthritis in vitro correlates with enhanced binding to extracellular matrix proteins , 1997, Annals of the rheumatic diseases.

[46]  S. Nagataki,et al.  TNF‐α‐mediated expression of membrane‐type matrix metalloproteinase in rheumatoid synovial fibroblasts , 1996, Immunology.

[47]  G. Firestein.  Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? , 1996, Arthritis and rheumatism.

[48]  J. Kriegsmann,et al.  Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. , 1996, The American journal of pathology.

[49]  P. Robbins.  Gene therapy protocols , 1996 .

[50]  H. Inoue,et al.  Expression of Fas antigen and Fas ligand in the rheumatoid synovial tissue. , 1996, Clinical immunology and immunopathology.

[51]  P. Isomäki,et al.  The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[52]  A. Koch,et al.  Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[53]  U. Müller-Ladner,et al.  Ultrastructural demonstration of apoptosis, Fas and Bcl-2 expression of rheumatoid synovial fibroblasts. , 1996, The Journal of rheumatology.

[54]  R. Spangler,et al.  Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. , 1996, Seminars in arthritis and rheumatism.

[55]  P. Lipsky,et al.  A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis , 1996 .

[56]  S. Yamashita,et al.  Localisation of apoptosis and expression of apoptosis related proteins in the synovium of patients with rheumatoid arthritis. , 1996, Annals of the rheumatic diseases.

[57]  Simon C Watkins,et al.  Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. , 1996, Human gene therapy.

[58]  P. Robbins,et al.  Pathways to gene therapy in rheumatoid arthritis. , 1996, Current opinion in rheumatology.

[59]  M. Feldmann,et al.  Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.

[60]  J. Sinacore,et al.  Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[61]  B. Manger,et al.  Biologic agents in the treatment of inflammatory rheumatic diseases. , 1995, Current opinion in rheumatology.

[62]  R. Kinne,et al.  [Proliferation of T-cells, macrophages, neutrophilic granulocytes and fibroblast-like cells in the synovial membrane of patients with rheumatoid arthritis]. , 1996, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[63]  T. Sawai,et al.  Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. , 1995, Annals of the rheumatic diseases.

[64]  B. Dijkmans,et al.  A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[65]  U. Müller-Ladner,et al.  Oncogenes in rheumatoid arthritis. , 1995, Rheumatic diseases clinics of North America.

[66]  E. Karran,et al.  In vivo model of cartilage degradation--effects of a matrix metalloproteinase inhibitor. , 1995, Annals of the rheumatic diseases.

[67]  P. Roux‐Lombard,et al.  Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. , 1995, Arthritis and rheumatism.

[68]  D. Haskard,et al.  Cell adhesion molecules in rheumatoid arthritis. , 1995, Current opinion in rheumatology.

[69]  Brian Henderson,et al.  Mechanisms and models in rheumatoid arthritis , 1995 .

[70]  J. Dayer,et al.  Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritis , 1995 .

[71]  J. Banchereau,et al.  Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. , 1995, Journal of immunology.

[72]  F. O’Sullivan.  25 – Spontaneous Arthritis Models , 1995 .

[73]  Panayi Gs.  The pathogenesis of rheumatoid arthritis and the development of therapeutic strategies for the clinical investigation of biologics. , 1995 .

[74]  C. Brinckerhoff,et al.  Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? , 1994, Arthritis and rheumatism.

[75]  A. Levitzki,et al.  Signal-transduction therapy. A novel approach to disease management. , 1994, European journal of biochemistry.

[76]  Alexander Levitzki,et al.  Signal-transduction therapy , 1994 .

[77]  J. Kriegsmann,et al.  A new model for rheumatoid arthritis generated by engraftment of rheumatoid synovial tissue and normal human cartilage into SCID mice. , 1994, Arthritis and rheumatism.

[78]  Ho As,et al.  Interleukin-10 and its receptor. , 1994 .

[79]  G. Firestein,et al.  Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[80]  M. Kohli,et al.  Local proliferation of fibroblast-like synoviocytes contributes to synovial hyperplasia. Results of proliferating cell nuclear antigen/cyclin, c-myc, and nucleolar organizer region staining. , 1994, Arthritis and rheumatism.

[81]  M. Eichelberger,et al.  Prominent usage of V beta 8.3 T cells in the H-2Db-restricted response to an influenza A virus nucleoprotein epitope. , 1993, Journal of immunology.

[82]  A. Vladutiu,et al.  The severe combined immunodeficient (SCID) mouse as a model for the study of autoimmune diseases , 1993, Clinical and experimental immunology.

[83]  R. Gay,et al.  Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? , 1993, Annals of the rheumatic diseases.

[84]  H. Hashimoto,et al.  Beta 1 integrin-mediated interaction with extracellular matrix proteins regulates cytokine gene expression in synovial fluid cells of rheumatoid arthritis patients , 1993, The Journal of experimental medicine.

[85]  J. Wilkins,et al.  Beta 1 (CD29) integrin expression in rheumatoid synovial membranes: an immunohistologic study of distribution patterns. , 1993, The Journal of rheumatology.

[86]  F. Sánchez‐Madrid,et al.  The role of adhesion molecules in the pathogenesis of rheumatoid arthritis. , 1993, Autoimmunity.

[87]  G. Firestein,et al.  Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium. , 1992, The American journal of pathology.

[88]  M. Harigai,et al.  Interleukin 1 and tumor necrosis factor-alpha synergistically increase the production of interleukin 6 in human synovial fibroblast. , 1991, Journal of clinical & laboratory immunology.

[89]  J. Mcghee,et al.  Expression of the collagenolytic and Ras-induced cysteine proteinase cathepsin L and proliferation-associated oncogenes in synovial cells of MRL/I mice and patients with rheumatoid arthritis. , 1990, Matrix.

[90]  K. Tomita,et al.  Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. , 1989, Annals of the rheumatic diseases.

[91]  Donald E. Mosier,et al.  Transfer of a functional human immune system to mice with severe combined immunodeficiency , 1988, Nature.

[92]  Y. Okada,et al.  Matrix metalloproteinases 1, 2, and 3 from rheumatoid synovial cells are sufficient to destroy joints. , 1987, The Journal of rheumatology.

[93]  H. Fassbender,et al.  Histomorphological basis of articular cartilage destruction in rheumatoid arthritis. , 1983, Collagen and related research.

[94]  C. Brinckerhoff,et al.  Survival of rheumatoid synovium implanted into nude mice. , 1981, The American journal of pathology.

[95]  Z. Werb,et al.  Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. , 1977, The New England journal of medicine.